Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oncolytic virus
Biotech
CG Oncology plans IPO ahead of phase 3 bladder cancer readout
Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public.
James Waldron
Jan 3, 2024 8:25am
Candel’s flame dims as layoffs hit 50% of the team
Nov 28, 2023 11:23am
CG raises $105M crossover round to fund phase 3 cancer trial
Aug 2, 2023 9:07am
AstraZeneca scraps Transgene pact in blow to oncolytic viruses
May 5, 2023 7:15am
BIO: Biotechs try to land coveted Big Pharma licensing deals
Feb 8, 2023 11:30am
Souped-up oncolytic virus warms up cold brain cancer tumors
Nov 11, 2022 12:56pm